Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Publication year range
1.
Actas dermo-sifiliogr. (Ed. impr.) ; 115(4): 368-373, Abr. 2024. ilus
Article in Spanish | IBECS | ID: ibc-231993

ABSTRACT

La inmunosupresión farmacológica de los pacientes trasplantados de órgano solido constituye un importante factor de riesgo tanto para la aparición de queratosis actínicas (QA) como para su progresión a carcinomas escamosos (CE). El tratamiento tanto de las lesiones clínicas como preclínicas en este grupo de pacientes es obligatorio debido a la elevada posibilidad de evolución a CE. Por otra parte, la prevención presenta también un papel importante que debemos tener en cuenta. Existen un gran número de estudios realizados en pacientes inmunocompetentes sobre el tratamiento y la prevención de QA, pero no en pacientes inmunosuprimidos. Esta revisión pretende resumir el conocimiento actual sobre los tratamientos y medidas de prevención de la QA en loas pacientes trasplantados de órgano sólido.(AU)


Pharmacological immunosuppression in solid organ transplant recipients is a significant risk factor in the occurrence of actinic keratosis (AK) and later progression into squamous cell carcinomas (SCC). Treating clinical and preclinical lesions is mandatory in this group of patients due to the high changes of progression into SCC. On the other hand, prevention of AK should be considered because it plays a crucial role.Several studies have been published on immunocompetent patients, as well as on the management and prevention of AK, but not on immunosuppressed patients.This review aims to summarize the current knowledge on the management and prevention measures of AK in solid organ transplant recipients.(AU)


Subject(s)
Humans , Male , Female , Keratosis, Actinic/complications , Organ Transplantation , Immunocompromised Host , Dermatitis , Keratosis, Actinic/drug therapy , Dermatology , Skin Diseases , Carcinoma, Squamous Cell
2.
Actas dermo-sifiliogr. (Ed. impr.) ; 115(4): T368-T373, Abr. 2024. ilus
Article in English | IBECS | ID: ibc-231994

ABSTRACT

La inmunosupresión farmacológica de los pacientes trasplantados de órgano solido constituye un importante factor de riesgo tanto para la aparición de queratosis actínicas (QA) como para su progresión a carcinomas escamosos (CE). El tratamiento tanto de las lesiones clínicas como preclínicas en este grupo de pacientes es obligatorio debido a la elevada posibilidad de evolución a CE. Por otra parte, la prevención presenta también un papel importante que debemos tener en cuenta. Existen un gran número de estudios realizados en pacientes inmunocompetentes sobre el tratamiento y la prevención de QA, pero no en pacientes inmunosuprimidos. Esta revisión pretende resumir el conocimiento actual sobre los tratamientos y medidas de prevención de la QA en loas pacientes trasplantados de órgano sólido.(AU)


Pharmacological immunosuppression in solid organ transplant recipients is a significant risk factor in the occurrence of actinic keratosis (AK) and later progression into squamous cell carcinomas (SCC). Treating clinical and preclinical lesions is mandatory in this group of patients due to the high changes of progression into SCC. On the other hand, prevention of AK should be considered because it plays a crucial role.Several studies have been published on immunocompetent patients, as well as on the management and prevention of AK, but not on immunosuppressed patients.This review aims to summarize the current knowledge on the management and prevention measures of AK in solid organ transplant recipients.(AU)


Subject(s)
Humans , Male , Female , Keratosis, Actinic/complications , Organ Transplantation , Immunocompromised Host , Dermatitis , Keratosis, Actinic/drug therapy , Dermatology , Skin Diseases , Carcinoma, Squamous Cell
3.
Actas Dermosifiliogr ; 115(4): T368-T373, 2024 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-38336247

ABSTRACT

Pharmacological immunosuppression in solid organ transplant recipients is a significant risk factor in the occurrence of actinic keratosis (AK) and later progression into squamous cell carcinomas (SCC). Treating clinical and preclinical lesions is mandatory in this group of patients due to the high changes of progression into SCC. On the other hand, prevention of AK should be considered because it plays a crucial role. Several studies have been published on immunocompetent patients, as well as on the management and prevention of AK, but not on immunosuppressed patients. This review aims to summarize the current knowledge on the management and prevention measures of AK in solid organ transplant recipients.


Subject(s)
Carcinoma, Squamous Cell , Keratosis, Actinic , Organ Transplantation , Skin Neoplasms , Humans , Keratosis, Actinic/drug therapy , Skin Neoplasms/etiology , Skin Neoplasms/prevention & control , Skin Neoplasms/pathology , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/prevention & control , Carcinoma, Squamous Cell/pathology , Immunocompromised Host , Organ Transplantation/adverse effects
4.
Actas Dermosifiliogr ; 115(4): 368-373, 2024 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-37925069

ABSTRACT

Pharmacological immunosuppression in solid organ transplant recipients is a significant risk factor in the occurrence of actinic keratosis (AK) and later progression into squamous cell carcinomas (SCC). Treating clinical and preclinical lesions is mandatory in this group of patients due to the high changes of progression into SCC. On the other hand, prevention of AK should be considered because it plays a crucial role. Several studies have been published on immunocompetent patients, as well as on the management and prevention of AK, but not on immunosuppressed patients. This review aims to summarize the current knowledge on the management and prevention measures of AK in solid organ transplant recipients.


Subject(s)
Carcinoma, Squamous Cell , Keratosis, Actinic , Organ Transplantation , Skin Neoplasms , Humans , Keratosis, Actinic/drug therapy , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Skin Neoplasms/prevention & control , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/prevention & control , Carcinoma, Squamous Cell/pathology , Immunocompromised Host , Organ Transplantation/adverse effects
5.
Actas Dermosifiliogr ; 2023 Nov 23.
Article in English, Spanish | MEDLINE | ID: mdl-38006969
SELECTION OF CITATIONS
SEARCH DETAIL
...